Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results
2016 ESMO CongressPaolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)
Related Videos
Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study (German Language Version)
Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with rela...
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell...
Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial
Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Results of the ACTIVE8 Trial
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with r...
Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)
Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung ca...
